Chebib FT, Torres VE. Autosomal Dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis. 2016;67(5):792–810.
Harris PC, Rossetti S. Determinants of renal disease variability in ADPKD. Adv Chronic Kidney Dis. 2010;17(2):131–9.
Meijer E, Boertien WE, Nauta FL, Bakker SJ, van Oeveren W, Rook M, et al. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Am J Kidney Dis. 2010;56(5):883–95.
Petzold K, Poster D, Krauer F, Spanaus K, Andreisek G, Nguyen-Kim TD, et al. Urinary biomarkers at early ADPKD disease stage. PLoS ONE. 2015;10(4):e0123555.
Ostroff C, Perrone RD, Czerwiec FS. Current challenges and perspectives on developing a clinical Trial Design for ADPKD. Clin J Am Soc Nephrol. 2022;17(10):1559–62.
Ix JH, Shlipak MG. The Promise of tubule biomarkers in kidney disease: a review. AAm J Kidney Dis. 2021;78(5):719–27.
Pabico RC, McKenna BA, Freeman RB. Renal tubular dysfunction in patients with cystic disease of the kidneys. Urology. 1998;51(5A Suppl):156–60.
Cassini MF, Kakade VR, Kurtz E, Sulkowski P, Glazer P, Torres R, et al. Mcp1 promotes macrophage-dependent cyst expansion in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2018;29(10):2471–81.
Kuehn EW, Park KM, Somlo S, Bonventre JV. Kidney injury molecule-1 expression in murine polycystic kidney disease. Am J Physiol Ren Physiol. 2002;283(6):F1326–36.
Parikh CR, Dahl NK, Chapman AB, Bost JE, Edelstein CL, Comer DM, et al. Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int. 2012;81(8):784–90.
Messchendorp AL, Meijer E, Boertien WE, Engels GE, Casteleijn NF, Spithoven EM, et al. Urinary biomarkers to identify autosomal dominant polycystic kidney disease patients with a high likelihood of disease progression. Kidney Int Rep. 2018;3(2):291–301.
Messchendorp AL, Meijer E, Visser FW, Engels GE, Kappert P, Losekoot M, et al. Rapid progression of autosomal dominant polycystic kidney disease: urinary biomarkers as predictors. Am J Nephrol. 2019;50(5):375–85.
Wang Y, Chen X, Song Y, Caballero B, Cheskin LJ. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73(1):19–33.
Nowak KL, Steele C, Gitomer B, Wang W, Ouyang J, Chonchol MB. Overweight and obesity and progression of ADPKD. Clin J Am Soc Nephrol. 2021;16(6):908–15.
Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, et al. Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2018;29(2):571–8.
Hopp K, Catenacci VA, Dwivedi N, Kline TL, Wang W, You Z, et al. Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease. iScience. 2022;25(1):103697.
Esposito K, Pontillo A, Ciotola M, Di Palo C, Grella E, Nicoletti G, et al. Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab. 2002;87(8):3864–6.
Tajik N, Keshavarz SA, Masoudkabir F, Djalali M, Sadrzadeh-Yeganeh HH, Eshraghian MR, et al. Effect of diet-induced weight loss on inflammatory cytokines in obese women. J Endocrinol Invest. 2013;36(4):211–5.
Christiansen T, Richelsen B, Bruun JM. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int J Obes (Lond). 2005;29(1):146–50.
Pastor-Soler NM, Li H, Pham J, Rivera D, Ho PY, Mancino V, et al. Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model. Am J Physiol Ren Physiol. 2022;322(1):F27–41.
Takiar V, Nishio S, Seo-Mayer P, King JD Jr., Li H, Zhang L, et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci. 2011;108(6):2462–7.
Christensen M, Jensen JB, Jakobsen S, Jessen N, Frokiaer J, Kemp BE, et al. Renoprotective effects of metformin are independent of organic cation transporters 1 &2 and amp-activated protein kinase in the kidney. Sci Rep. 2016;6:35952.
Chen XC, Wu D, Wu HL, Li HY, Yang C, Su HY et al. Metformin improves renal injury of MRL/lpr lupus-prone mice via the AMPK/STAT3 pathway. Lupus Sci Med. 2022;9(1).
Li J, Gui Y, Ren J, Liu X, Feng Y, Zeng Z, et al. Metformin protects against cisplatin-induced tubular cell apoptosis and acute kidney injury via ampkalpha-regulated autophagy induction. Sci Rep. 2016;6:23975.
Luque-Ramirez M, Escobar-Morreale HF. Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations. Horm Metab Res. 2010;42(11):815–20.
Esteghamati A, Rezvani S, Khajeh E, Ebadi M, Nakhjavani M, Noshad S. Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial. J Endocrinol Invest. 2014;37(12):1211–8.
Brosnahan GM, Wang W, Gitomer B, Struemph T, George D, You Z, et al. Metformin therapy in autosomal dominant polycystic kidney disease: a feasibility study. Am J Kidney Dis. 2022;79(4):518–26.
Irazabal MV, Mishra PK, Torres VE, Macura SI. Use of ultra-high field MRI in small rodent models of polycystic kidney disease for in vivo phenotyping and drug monitoring. J Vis Exp. 2015;100:e52757.
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26(1):160–72.
Malhotra R, Katz R, Jotwani V, Ambrosius WT, Raphael KL, Haley W, et al. Urine markers of kidney tubule cell injury and kidney function decline in sprint trial participants with CKD. Clin J Am Soc Nephrol. 2020;15(3):349–58.
Shi M, Ma L, Fu P. Role of fatty acid binding protein 4 (FABP4) in kidney disease. Curr Med Chem. 2020;27(22):3657–64.
Park S, Mathis KW, Lee IK. The physiological roles of apolipoprotein J/clusterin in metabolic and cardiovascular diseases. Rev Endocr Metab Disord. 2014;15(1):45–53.
Nadkarni GN, Rao V, Ismail-Beigi F, Fonseca VA, Shah SV, Simonson MS, et al. Association of urinary biomarkers of inflammation, injury, and fibrosis with renal function decline: the ACCORD Trial. Clin J Am Soc Nephrol. 2016;11(8):1343–52.
Griffin BR, You Z, Noureddine L, Gitomer B, Perrenoud L, Wang W, et al. KIM-1 and kidney disease progression in autosomal dominant polycystic kidney disease: HALT-PKD results. Am J Nephrol. 2020;51(6):473–9.
Zheng D, Wolfe M, Cowley BD Jr., Wallace DP, Yamaguchi T, Grantham JJ. Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2003;14(10):2588–95.
Segarra-Medrano A, Martin M, Agraz I, Vilaprinyo M, Chamoun B, Jatem E, et al. Association between urinary biomarkers and disease progression in adults with autosomal dominant polycystic kidney disease. Clin Kidney J. 2020;13(4):607–12.
Warner G, Hein KZ, Nin V, Edwards M, Chini CC, Hopp K, et al. Food Restriction ameliorates the development of polycystic kidney disease. J Am Soc Nephrol. 2016;27(5):1437–47.
Fu CP, Sheu WH, Lee IT, Lee WJ, Wang JS, Liang KW, et al. Weight loss reduces serum monocyte chemoattractant protein-1 concentrations in association with improvements in renal injury in obese men with metabolic syndrome. Clin Chem Lab Med. 2015;53(4):623–9.
Skurk T, Kolb H, Muller-Scholze S, Rohrig K, Hauner H, Herder C. The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. Eur J Endocrinol. 2005;152(6):863–8.
Coca SG, Nadkarni GN, Huang Y, Moledina DG, Rao V, Zhang J, et al. Plasma biomarkers and kidney function decline in early and established diabetic kidney disease. J Am Soc Nephrol. 2017;28(9):2786–93.
Carter CE, Katz R, Kramer H, de Boer IH, Kestenbaum BR, Peralta CA, et al. Influence of urine creatinine concentrations on the relation of albumin-creatinine ratio with cardiovascular disease events: the multi-ethnic study of atherosclerosis (MESA). Am J Kidney Dis. 2013;62(4):722–9.
Waikar SS, Sabbisetti VS, Bonventre JV. Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int. 2010;78(5):486–94.
KDIGO 2012 clinical. Practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;Suppl 3:1–150.
Bhavsar NA, Kottgen A, Coresh J, Astor BC. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) as predictors of incident CKD stage 3: the atherosclerosis risk in communities (ARIC) Study. Am J Kidney Dis. 2012;60(2):233–40.
Peralta CA, Katz R, Bonventre JV, Sabbisetti V, Siscovick D, Sarnak M, et al. Associations of urinary levels of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) with kidney function decline in the multi-ethnic study of atherosclerosis (MESA). Am J Kidney Dis. 2012;60(6):904–11.
Bullen AL, Katz R, Lee AK, Anderson CAM, Cheung AK, Garimella PS, et al. The SPRINT trial suggests that markers of tubule cell function in the urine associate with risk of subsequent acute kidney injury while injury markers elevate after the injury. Kidney Int. 2019;96(2):470–9.
Boertien WE, Meijer E, de Jong PE, ter, Horst GJ, Renken RJ, van der Jagt EJ et al. Short-term effects of tolvaptan in individuals with autosomal dominant polycystic kidney disease at various levels of kidney function. Am J Kidney Dis. 2015;65(6):833 – 41.
- The Renal Warrior Project. Join Now
- Source: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03643-6